Calcium Phosphate and Incretins

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gerhard Jahreis, University of Jena
ClinicalTrials.gov Identifier:
NCT01296997
First received: February 15, 2011
Last updated: November 6, 2012
Last verified: November 2012
  Purpose

The study was conducted to investigate the effect of a calcium phosphate supplementation on the secretion of incretins.


Condition Intervention
Healthy Men
Dietary Supplement: calcium phosphate
Other: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Influence of a Calcium Phosphate Supplementation on the Secretion of Incretins in Humans.

Resource links provided by NLM:


Further study details as provided by University of Jena:

Primary Outcome Measures:
  • secretion of incretins [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • concentration of minerals in plasma [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 10
Study Start Date: July 2010
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: calcium phosphate Dietary Supplement: calcium phosphate
the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
Placebo Comparator: placebo Other: placebo
the subjects consumed a bread without pentacalcium phosphate

  Eligibility

Ages Eligible for Study:   20 Years to 35 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy men

Exclusion Criteria:

  • intake of dietary supplements and chronic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01296997

Locations
Germany
Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology
Jena, Thuringia, Germany, 07743
Sponsors and Collaborators
University of Jena
Investigators
Principal Investigator: Gerhard Jahreis, Prof. Dr. Friedrich-Schiller-University Jena, Institute of Nutrition, Department of Nutritional Physiology
  More Information

No publications provided by University of Jena

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gerhard Jahreis, Prof. Dr. habil, University of Jena
ClinicalTrials.gov Identifier: NCT01296997     History of Changes
Other Study ID Numbers: LSEP H45-10
Study First Received: February 15, 2011
Last Updated: November 6, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by University of Jena:
calcium phosphate
incretins
human study

Additional relevant MeSH terms:
Calcium, Dietary
Incretins
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on July 22, 2014